Semaglutide's SELECT trial enrolled 17,604 adults with established cardiovascular disease; the primary endpoint was major adverse cardiovascular events at a median 34-month follow-up, met at a 20% hazard ratio reduction against placebo, published in the New England Journal of Medicine in October 2023. That population was already sick. APAC family-office capital in Q2 2026 is pricing GLP-1 receptor agonists as a primary-prevention aging asset. The SELECT trial is a secondary-prevention cardiovascular trial.

NMPA's Center for Drug Evaluation approved semaglutide for type 2 diabetes management and is reviewing a supplemental obesity indication; neither filing names a biological-age primary endpoint. HSA Singapore and TGA's Advisory Committee on Prescription Medicines approved the weight-management indication on cardiometabolic grounds in 2022 and 2023 respectively. No APAC regulator has a biological-aging drug indication. Novo Nordisk's EVOKE trial tested semaglutide in early Alzheimer's disease patients with the Clinical Dementia Rating-Sum of Boxes scale as its primary endpoint and reported no significant separation from placebo at CTAD in October 2024. The biological-aging thesis embedded in the current APAC GLP-1 position requires NMPA's Center for Drug Evaluation to create a regulatory pathway with no precedent in its published indication frameworks, and Novo Nordisk's published Phase 3 trial record contains no study with aging biology as a primary endpoint.